SPRAVATO® Esketamine Treatment

For those with treatment-resistant depression, SPRAVATO® (esketamine) may offer a new path forward. This FDA-approved therapy works differently from standard antidepressants and can bring an immediate sense of relief.

A colorful abstract illustration with various geometric shapes, lines, and patterns on a black background. A large teal curve partially covers the right side.

Schedule A Consultation

Two women lying on grass, smiling and looking at each other, one wearing a white top and the other wearing a blue and black striped sweater.

SPRAVATO® is an FDA-approved nasal spray used to treat adults with Treatment-Resistant Depression (TRD). Unlike traditional antidepressants, SPRAVATO® is administered in a clinical setting under medical supervision. This treatment offers a new option for patients who haven’t found relief through standard therapies.
SPRAVATO® targets NMDA receptors in the brain, increasing levels of glutamate—a key neurotransmitter that supports mood regulation. This unique mechanism can deliver rapid antidepressant effects, sometimes reducing symptoms within 24 hours. Each treatment session lasts about two hours and takes place in-office to ensure safety and close monitoring during and after administration.
This treatment is designed for individuals with depression that has not improved with traditional antidepressants. With careful supervision, SPRAVATO® provides a safe and structured path toward relief for those seeking a fast-acting alternative to conventional options.